Picture of DarioHealth logo

DRIO — DarioHealth News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

DarioHealth Q1 revenue rises sequentially, operating loss narrows on cost reductions

Overview

Digital health platform's Q1 revenue rose sequentially but fell yr/yr due to one-time prior revenue

Operating expenses fell 21% yr/yr and operating loss narrowed 22% yr/yr

Company added 10 new accounts and expanded channel partnerships, now reaching 116 mln covered lives

Outlook

DarioHealth sees potential for increased scale and operating leverage from its channel-led commercial model

Result Drivers

REVENUE MIX SHIFT - Year-over-year revenue fell mainly due to the non-recurrence of $1.3 mln in pharmaceutical customer revenue as co shifted focus to recurring B2B2C business

CHANNEL PARTNER GROWTH - Sequential revenue growth was driven by onboarding of new clients from channel partners and increased MSK product sales

COST REDUCTIONS - Operating expenses decreased year-over-year and quarter-over-quarter, mainly due to increased operational efficiency

Company press release: ID:nPn7yVGPva

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueBeat$5.60 mln$5.45 mln (2 Analysts)
Q1 Net IncomeBeat-$8.20 mln-$8.90 mln (2 Analysts)
Q1 Operating IncomeMiss-$7.30 mln-$6.50 mln (2 Analysts)
Q1 Gross Profit$3.20 mln
Q1 Operating Expenses$10.50 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for DarioHealth Corp is $18.00, about 107.4% above its May 12 closing price of $8.68 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on DarioHealth

See all news